MK-5890-003
Phase 2 Withdrawn
Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer
Phase 2 Withdrawn
Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)
Phase 2 Withdrawn
Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN
Phase 2 Withdrawn
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
Phase 2 Withdrawn
Neoadjuvant Nimotuzumab Plus Gemcitabine and Carboplatin in Unresectable Stage III Squamous Cell Lung Carcinoma
Phase 2 Withdrawn
APPEAL
Phase 2 Withdrawn
NAJSCR
Phase 2 Withdrawn
Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer
Phase 2 Withdrawn
Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer
Phase 2 Withdrawn
Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer
Phase 2 Withdrawn
NSCLC
Phase 2 Withdrawn
A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer
Phase 2 Withdrawn
Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial
Phase 2 Withdrawn
Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer
Phase 2 Withdrawn
APX005M
Phase 2 Withdrawn
AdvanTIG-211
Phase 2 Withdrawn
CRATER
Phase 2 Withdrawn
RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC
Phase 2 Withdrawn
Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women
Phase 2 Withdrawn
CheckMate 9TN
Phase 2 Withdrawn
A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer
Phase 2 Withdrawn
Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients
Phase 2 Withdrawn
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
Phase 2 Withdrawn
Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer
Phase 2 Withdrawn
PANDoRA
Phase 2 Withdrawn
CATHAYA
Phase 2 Withdrawn
Hypofractionated Radiotherapy With Carboplatin and Paclitaxel in Non-Small Cell Lung Cancer
Phase 2 Withdrawn
CECAVI
Phase 2 Withdrawn
HIPEC
Phase 2 Withdrawn
A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Phase 2 Withdrawn
Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer
Phase 2 Withdrawn
ES01
Phase 2 Withdrawn
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
Phase 2 Withdrawn
Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer
Phase 2 Withdrawn
Gemcitabine Hydrochloride and Carboplatin With or Without MK-0646 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Phase 2 Withdrawn
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
Phase 2 Withdrawn
A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel
Phase 2 Withdrawn
Enzastaurin, Carboplatin, and Gemcitabine With or Without Bevacizumab in Treating Patients With Recurrent, Stage IIIB, or Stage IV Non-Small Cell Lung Cancer
Phase 2 Withdrawn
Carboplatin, Temozolomide, and Filgrastim in Treating Patients With Newly Diagnosed or Recurrent High-Grade Glioma
Phase 2 Withdrawn
Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib
Phase 2 Withdrawn
Abraxane and RT for Non-Small Cell Lung Cancer (NSCLC)
Phase 2 Withdrawn
A Phase II Trial of Proton Pump Inhibitors With Chemotherapy in Patients With Metastatic Head and Neck Cancer
Phase 2 Withdrawn
Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin
Phase 2 Withdrawn
Carboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With Chemotherapy
Phase 2 Withdrawn